PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim. Based on the RE-LY study to evaluate the cost-effectiveness of dabigatran etexilate versus warfarin prescribed in “real-world” settings f...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
Формат: Artigo
Язык:Inglês
Опубликовано: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Серии:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Предметы:
dabigatran etexelate
warfarin
vitamin k antagonists
atrial fibrillation
pharmacoecomomics
clinic-economic evaluation
cost-effectiveness
markov modeling
Online-ссылка:https://www.rpcardio.com/jour/article/view/397
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы